Pomdoctor Limited Reports 16.2% Growth in Revenues for First Half of Fiscal 2025

Pomdoctor Limited Reports Financial Results for H1 FY2025

Pomdoctor Limited, a prominent platform for online medical services aimed at chronic diseases in China, has released its unaudited financial results for the first half of fiscal 2025, concluding on June 30. The company showed remarkable resilience in its operations despite external market challenges. During this period, Pomdoctor experienced a net revenue growth of 16.2%, reaching RMB 174.5 million (approximately USD 24.4 million), compared to RMB 150.2 million in the same timeframe of 2024.

The company's CEO, Mr. Zhenyang Shi, reflected on Pomdoctor's strategic approach, mentioning, "Our deliberate efforts focused on balancing effective business growth with operational discipline have been fruitful. The first half of the fiscal year was a testament to our ongoing adaptability to the competitive landscape and shifting economic realities."

A standout factor in Pomdoctor's financial results was the substantial increase of 83.2% in their online pharmacy segment, revealing the growing reliance on digital solutions in healthcare management. This growth in online pharmacy revenues significantly contributed to the overall increase in net revenues from the internet hospital services, which rose by 82.4% year over year. Collaboration with pharmaceutical manufacturers has further strengthened this upward trend, enhancing online sales opportunities through their platform.

Despite the increased revenues, Pomdoctor faced higher costs associated with their revenue-generating efforts, specifically in sales and marketing. These expenses rose by 11.6%, totaling RMB 27.8 million (approximately USD 3.9 million). Nevertheless, the company successfully maintained a consistent gross profit margin of 16.2%, resulting in a gross profit increase of 16.3% from the previous year, amounting to RMB 28.3 million (around USD 4.0 million).

Despite the positive growth indicators, Pomdoctor reported a net loss of RMB 19.9 million (about USD 2.8 million) for the first half of 2025, compared to a loss of RMB 14.0 million for the same period in 2024. The increased loss primarily stemmed from investment in operational initiatives aimed at sustainable growth, alongside the rise in costs associated with acquiring customers and expanding their doctor network.

Cash and cash equivalents amounted to RMB 5.7 million (approximately USD 0.8 million), a decline from RMB 7.7 million at the end of 2024. The company’s cash flow analysis revealed a net cash utilization of RMB 15 million (USD 2.1 million) in operations during the six months leading up to June 30, 2025.

Importantly, Pomdoctor's recent initial public offering (IPO) in October added a critical financial cushion for future developments. The company raised approximately RMB 163.5 million (USD 23 million), which provides further strategic opportunities for growth and operational execution.

Looking forward, Mr. Zhenyang Shi expressed optimism regarding the company's trajectory, stating, "We are steadfast in our mission to enhance operational performance while generating long-term value for our shareholders. Our focus remains on improving healthcare accessibility across China through our digital platforms."

Pomdoctor Limited aims to utilize these financial results to guide its strategy as it navigates the evolving landscape of healthcare services in China, underlining its commitment to bridging healthcare access and efficiency through technology. As they engage in favorable partnerships and innovate their service offerings, Pomdoctor endeavors to position itself as a trustworthy leader in the online medical services sector.